Processa Pharmaceuticals, Inc. (PCSA) stock
PCSANasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.70−0.03 (-1.73%)
Close on Nov 18, 2026Market cap $4.75MP/E –Yield –
Processa Pharmaceuticals free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Processa Pharmaceuticals's free cash flow for the twelve months ending Dec 31, 2024 was -$11.25M. For fiscal 2024 it was -$11.25M. The highest annual figure on record is -$873.31K in fiscal 2015.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -$11.25M | – |
| FY2023 | Dec 31, 2023 | -$8.07M | – |
| FY2017 | Dec 31, 2017 | -$1.68M | – |
| FY2016 | Dec 31, 2016 | -$2.18M | – |
| FY2015 | Dec 31, 2015 | -$873.31K | – |
| FY2014 | Dec 31, 2014 | -$2.70M | – |
| FY2013 | Dec 31, 2013 | -$2.57M | – |
| FY2012 | Dec 31, 2012 | -$2.23M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | -$2.25M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.12M | – |
| Q1 FY2017 | Mar 31, 2017 | -$59.58K | – |
See a number that looks wrong?